The Role of Hope and Faith In Fighting Prostate Cancer

You are sitting in your doctor’s office listening to the doctor tell you that you have prostate cancer! Immediately, numbness and disbelief creep into your reality. Over time, the news sinks in and you begin to understand the diagnosis, you have cancer. Your world has been changed and will never be the same. All of [...]

Where Are The Prostate Cancer Mets Located?

Sometimes I have heard the question, Where can prostate cancer metastasis (met) be found? Usually, the question really means, how can my met in my spleen or liver (or what ever) come from my prostate cancer? In realty, prostate cancer tumors can develop anywhere in the human body! There was a study of human cadavers [...]

Announcing A Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients

For our European readers who have not yet started, but are getting ready to start hormone deprivation therapy (ADT), there is a new clinical trial you should consider. This trial is evaluating MDV3100 monotherapy as the first hormonal treatment of patients with prostate cancer. Enrolled men would not have had any previous hormonal therapies for [...]

New Approved Drugs Keep Us in the Proverbial Pickle

Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]

A Personal Request – Help Us Save The Prostate Cancer Research Program at the Department of Defense

Federal research funding for prostate cancer accounts for around $400 million per year. The Prostate Cancer Research Program at the Department of Defense has received about $80 million per year since 2001. Funding at the PCRP has accelerated the clinical trial process for several drugs over the past couple of years including the recently approved [...]

Go to Top